Selecta (RUS) LLC, the Russian Subsidiary of the US Company Selecta Biosciences, Inc., Opens a Research Center in Khimki

Khimki, Moscow Oblast' | November 28, 2012

US Embassy Deputy Chief of Mission (DCM) Sheila Gwaltney speaking at the research center opening.

During the press conference.

Selecta (RUS) LLC, the Russian subsidiary of the US company Selecta Biosciences, Inc., opened a research center in Khimki on November 28. RUSNANO will invest up to $25 million in Selecta in several tranches. An opening ceremony was attended by RUSNANO CEO Anatoliy Chubais, President and Chief Executive Officer of Selecta Biosciences, Inc. Werner Cautreels, Ph.D, and US Embassy Deputy Chief of Mission (DCM) Sheila Gwaltney.

At the new research center Russian and American scientists will develop synthetic nanoparticle vaccines for the treatment and prevention of cancer as well as respiratory, infectious, autoimmune and allergic diseases. One product currently in the clinical test phase is a nicotine vaccine to aid people to quit smoking. Selecta Biosciences, Inc. is a clinical stage biotechnology company with headquarters in Boston, Massachusetts. Its vaccines are developed based on the tSVP™ nanotechnology platform which was invented at the Massachusetts Institute of Technology and the Harvard Medical School.

“We congratulate Selecta Biosciences and Selecta Russia on the inauguration of facilities here” DCM Gwaltney said in her remarks at the opening. “We are also pleased to see the benefit of two-way business investment between our two countries. Both Rusnano and U.S.-based venture capital companies have made financial investments in Selecta. And now the economic engagement across the countries’ borders continues to expand with this site for Selecta Russia, which will benefit this country by applying Russian scientific resources and meeting the needs of the Russian market.”